Skip to main content
SpringerLink
Log in

Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and objective: Metformin is an effective treatment for type 2 diabetes mellitus. The pharmacokinetic characteristics of the conventional immediate-release (IR) formulation of metformin (Glucophage®), however, necessitate two- or three-times-daily dosing. Development of a novel extended-release (XR) formulation of metformin (Glucophage® XR) using GelShield Diffusion System technology provides a once-daily dosing option. The objective of this study was to assess the steady-state pharmacokinetics of metformin XR tablets.

Study design: This was an open-label, multiple-dose, five-regimen, twosequence clinical study lasting 5 weeks.

Methods: Subjects were 16 healthy volunteers aged 18–40 years. Three 1-week regimens of metformin XR (500, 1000 and 1500mg once daily) were administered sequentially. Subjects were alternately given either metformin XR 2000mg once daily or metformin IR 1000mg twice daily during weeks 4 and 5. The pharmacokinetic properties of metformin XR were assessed on two separate days at steady state and compared with those of metformin IR.

Results: Absorption of metformin XR was slower than that of metformin IR (time to maximum plasma concentration = 7 versus 3 hours). Maximum plasma concentrations (Cmax) following the administration of metformin XR 2000mg once daily was 36% higher than that following the evening dose of metformin IR 1000mg twice daily. The extent of absorption, determined by area under the plasma concentration-time curve (AUC), was equivalent for both formulations. The mean accumulation ratio of metformin XR was 1.0, indicating no accumulation with multiple-dose administration. Intrasubject variabilities in Cmax and AUC of metformin were comparable between metformin XR and metformin IR. This novel formulation of metformin XR was well tolerated at single doses up to 2000mg once daily for 7 days, and adverse events were similar to those reported with metformin IR.

Conclusion: The pharmacokinetic parameters of metformin XR tablet using GelShield Diffusion System technology were similar to those of metformin IR. Metformin XR was well tolerated at single doses up to 2000mg once daily.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Fig. 3
Table II
Fig. 4
Fig. 5
Table III
Table IV

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Vidon N, Chaussade S, Noel M, et al. Metformin in the digestive tract. Diabetes Res Clin Pract 1988; 4: 223–9

    Article  PubMed  CAS  Google Scholar 

  2. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. J Clin Pharmacol 1981; 12: 235–46

    CAS  Google Scholar 

  3. Sambol NC, Chiang J, O’Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin dependent diabetes mellitus. J Clin Pharmacol 1996; 36: 1012–21

    Article  PubMed  CAS  Google Scholar 

  4. Sambol NC, Brookes LG, Chiang J, et al. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 1996; 42: 510–2

    Article  PubMed  CAS  Google Scholar 

  5. Bretnall AE, Clarke GS. Metformin hydrochloride. In: Brittain HG, editor. Analytical profiles of drug substances and excipients. Vol. 25. San Diego (CA): Academic Press, 1998: 243–93

    Chapter  Google Scholar 

  6. Marathe PH, Wen Y, Norton J, et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol 2000; 50: 325–32

    Article  PubMed  CAS  Google Scholar 

  7. Timmins P, Dennis AB, Vyas KA, inventors. Bristol-Myers Squibb Company, assignee. Biphasic controlled release delivery system for high solubility pharmaceuticals and method. US patent 6,475,521. 2002 Nov 5

  8. Caldwell LJ, Gardener CR, Cargill RC, inventors. Merck and Co, Inc, assignee. Drug delivery device which can be retained in the stomach for a controlled period of time. US patent 4,767,627. 1988 Aug 30

  9. Urquart J, Theeuwes F, inventors. Alza Corporation, assignee. Drug delivery system comprising a reservoir containing a plurality of tiny pills. US patent 4,434,153. 1984 Feb 28

  10. Shell JW, inventor. DepoMed Systems, Inc, assignee. Sustained-release oral drug dosage form. US Patent 5,007,790. 1991 Apr 16

    Google Scholar 

  11. Shell JW, inventor. DepoMed Systems, Inc, assignee. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms. World patent WO 9318755. 1993 Sep 30

  12. Shell JW, inventor. DepoMed Sytems, Inc, assignee. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms. US patent 5,582,837. 1996 Dec 10

  13. Hebden JM, Gilchrist PJ, Blackshaw E, et al. Night-time quiescence and morning activation in the human colon: effect on transit of dispersed and large single unit formulations. Eur J Gastroenterol Hepatol 1999; 11: 1379–85

    Article  PubMed  CAS  Google Scholar 

  14. Glucophage (metformin hydrochloride) and glucophage XR (metformin hydrochloride extended-release tablets) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2002

  15. Data on file, Bristol-Myers Squibb Company, 1998

  16. Di Colo G, Falchi S, Zambito Y. In vitro evaluation of a system for Ph-controlled peroral delivery of metformin. J Control Release 2002; 80: 119–28

    Article  PubMed  Google Scholar 

  17. Yuen KH, Peh KK, Tan BL. Relating in vitro/in vivo data of two controlled-release metformin formulations. Drug Dev Ind Pharm 1999; 25: 613–8

    Article  PubMed  CAS  Google Scholar 

  18. Pentikainen PJ. Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained-release products. Int J Clin Pharmacol Ther Toxicol 1986; 24: 213–20

    PubMed  CAS  Google Scholar 

  19. Noel DS. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. J Int Biomed Inform Data 1980; 1: 9–20

    CAS  Google Scholar 

  20. Karttunen P, Uusitupa M, Lamminsivu U. The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. Int J Clin Pharmacol Ther Toxicol 1983; 21: 31–6

    PubMed  CAS  Google Scholar 

  21. Gusler G, Gorsline J, Levy G, et al. Pharmacokinetics of a metformin gastro-retentive tablets in healthy volunteers. J Clin Pharmacol 2001; 41: 655–61

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Funding for the study was provided by Bristol-Myers Squibb Company, Pharmaceutical Research Institute, Moreton, UK, and Princeton, New Jersey, USA.

Author information

Authors and Affiliations

  1. Bristol-Myers Squibb Company, Pharmaceutical Research Institute, Reeds Lane, Moreton, CH46 1QW, UK

    Peter Timmins

  2. Bristol-Myers Squibb Company, Pharmaceutical Research Institute, Princeton, New Jersey, USA

    Steve Donahue, Jeff Meeker & Punit Marathe

Authors
  1. Peter Timmins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steve Donahue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeff Meeker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Punit Marathe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Timmins.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Timmins, P., Donahue, S., Meeker, J. et al. Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation. Clin Pharmacokinet 44, 721–729 (2005). https://doi.org/10.2165/00003088-200544070-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200544070-00004

Keywords

Search

Navigation